The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

in patients with severe aortic stenosis who were not suitable candidates for surgery, transcatheter aortic-valve implantation (TAVI) was associated with reduction in symptoms and death from any ...

Transcatheter aortic valve implantation has been established as an alternative treatment option for patients with severe aortic stenosis presenting with prohibitively high surgical risk or ...

The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

Unfortunately, there is no way to prevent aortic stenosis from progressing. The goal is to monitor it until it becomes severe ...

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system ...

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter aortic valve replacement (TAVR) had similar rates of death or disabling ...

Compared with usual care, a system of electronic provider notification more often enabled patients diagnosed with severe ...

LOS ANGELES -- Survival outcomes favored mechanical valves for isolated surgical aortic valve replacement (SAVR) for people until age 60, after which a tissue valve may start to have an advantage ...

CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal ...

Patients who underwent transcatheter aortic ... open heart surgery in patients who are eligible for either procedure. The study was funded by JenaValve, maker of the Trilogy valve.

Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years ...